In breast cancer and in prostate cancer, NFκB-driven signaling activates positive feedback signals between cancer and stromal cells, whereby canonical, p65-driven signals form positive feedback loops with the non-canonical NFκB pathway, increasing resistance to hormones and to endocrine therapy [161]. This evidence concerns the gene NFKB1 and prostate cancer.